ASH2023 ｜中国研究最全汇总，看这一篇就够了

一年一度的美国血液学会（ASH）年会是全球血液学领域最受瞩目的国际学术盛会之一，每年都吸引着来自世界各地的专家学者。2023年第65届ASH年会将于12月9日-12日在美国圣迭戈召开，会议将公布最顶尖的血液学领域研究摘要，探讨如何改善患者的管理和治疗、探寻新的治疗方案。

近年来，中国临床研究发展迅速，中国在世界血液学领域的影响力也日益增加。作为中国疫情政策开放后的第一届ASH年会，相信今年我国会有更多的专家学者踏上ASH年会的舞台，分享他们的研究成果、观点和经验。

根据当地时间11月2日上午9:00 ASH官网公布的摘要，医脉通小编检索到今年我国专家共有64篇研究入选Oral Abstracts ，466篇研究入选Poster Abstracts，相比去年增长47%！医脉通特将研究相关信息整理如下，以飨读者。

 

Oral Abstracts

 

摘要号/标题

报告人

7 Bromodomain Protein BRD4 Is a Transcriptional Repressor of Terminal Erythropoiesis By Interacting with EHMT1/2

Meng Zhang，浙江大学医学院附属第一医院

 

10 A Mediator Switch Tunes Transcription Pausing to Drive Erythropoiesis

Hsiang-Ying Lee，北京大学

 

55 Selinexor in Combination with Venetoclax and Azacitidine for Newly Diagnosed (ND) Unfit Acute Myeloid Leukemia (AML): A Multicenter, Open-Label Prospective Study

杨莉，上海交通大学医学院附属同仁医院

 

83 Loss of DDX3X Function Promotes CLL Progression By Facilitating NOTCH1 mRNA Translation

苗毅，江苏省人民医院

 

101 A Multi-Omic Single-Cell Landscape of Cytokine Release Syndrome in Multiple Myeloma Patients after Anti-BCMA CAR-T Cell Therapy

胡永仙，浙江大学医学院附属第一医院

 

117 Discovery of BCL-XL Heterobifunctional Degrader with Potentially Improved Therapeutic Window and Minimal Platelet Toxicity for Hematological Malignancies

Yang Xie，北京星亢原生物科技有限公司

 

123 Development and Validation of Deep Learning Model for Diagnosis and Subtypes Differentiation of Myeloproliferative Neoplasms Using Clinical Data and Digital Pathology

Zhongxun Shi，江苏省人民医院

 

139 Mitochondrial tRNA Pseudouridylation Regulates Erythropoiesis Via the mTOR Signaling Pathway: Implications for Mlasa and Treatment Strategies

Yajing Chu，中国医学科学院血液病医院（中国医学科学院血液学研究所）

 

142 The ATF4-RPS19BP1 Axis Modulates Ribosome Biogenesis to Promote Erythropoiesis

Zhaofeng Zheng，中国医学科学院血液病医院（中国医学科学院血液学研究所）

 

157 An Entirely Oral Regimen of Oral-Arsenic Trioxide/All-Trans Retinoic Acid/Ascorbic Acid in Newly-Diagnosed Acute Promyelocytic Leukaemia (APL): Updated Results of an Ongoing Multicentre Trial

Harinder Gill，香港大学

 

188 Clinical Implications of CSF-Ctdna in CNS Involvement of Newly Diagnosed Diffuse Large B Cell Lymphoma: An Improvement of Diagnosis, Treatment and Evaluation

梁金花，江苏省人民医院

 

189 Diagnostic and Prognostic Value of Circulating Cell-Free DNA in Cerebrospinal Fluid and Plasma in Newly Diagnosed Diffuse Large B Cell Lymphoma

李炳宗，苏州大学附属第二医院

 

218 Naturally Selected CD7-Targeted Chimeric Antigen Receptor (CAR)-T Cell Therapy for Refractory/Relapsed Acute Myeloid Leukemia: Phase I Clinical Trial

陆佩华，北京陆道培医院

 

234 Short-Term Blinatumomab As a Bridge Therapy for Hematopoietic Stem Cell Transplantation in B-Cell Acute Lymphoblastic Leukemia with Low Leukemia Burden

Hang Zhang，四川大学华西医院

 

239 CD7 Chimeric Antigen Receptor T-Cell Therapy Bridging to Allogeneic Hematopoietic Stem Cell Transplantation Remarkably Improved Long-Term Disease-Free Survival in Refractory/Relapsed T-Cell Acute Lymphoblastic Leukemia/Lymphoma

李智慧，北京高博博仁医院

 

278 Gpibα Caar-T Cells Induce Autoreactive B Cells Elimination to Treat Immune Thrombocytopenia

梅恒，华中科技大学同济医学院附属协和医院

 

279 Iguratimod Regulates CD4+ T-Cell Homeostasis and Function By Restoring PINK1/Parkin-Mediated Mitophagy in Immune Thrombocytopenia

Yuxiu Chen，北京大学人民医院

 

281 Notch1 Regulates Hepatic Thrombopoietin Production

乔建林，徐州医科大学

 

286 The Impacts of Genetic Polymorphisms on the Von Willebrand Factor Level in Type 1 Von Willebrand Disease

Yeu-Chin Chen，台湾三军总医院

 

289 CD74+ Leukemia-Associated Macrophages Supporess T Cell Immune Surveillance and Promote Leukemic Cell Growth in Acute Myeloid Leukemia

Guo Qiu，南方医科大学南方医院

 

304 A Multicenter, Open-Label, Single-Arm, Phase Ib Clinical Trial of HH2853 in the Treatment of Patients with Relapsed and/or Refractory Peripheral T-Cell Lymphoma

洪煌明，四川省肿瘤医院

 

305 Golidocitinib in Treating Refractory or Relapsed Peripheral T- Cell Lymphoma: Full Analysis of the Multinational Pivotal Study Results (JACKPOT8)

宋玉琴，北京大学肿瘤医院

 

306 A Multicenter Phase2 Trial of Linperlisib in Relapsed or Refractory Peripheral T/NK Cell Lymphomas

宋玉琴，北京大学肿瘤医院

 

320 Preliminary Results of a Phase 2 Study of IMM01 Combined with Azacitidine (AZA) As the First-Line Treatment in Adult Patients with Higher Risk Myelodysplastic Syndromes (MDS)

杨威，中国医科大学附属盛京医院

 

366 Deciphering the Impact of Donor Telomere Length on Allogeneic Transplantation Outcomes: Telomere Length Matters More Than Age

Hengwei Wu，浙江大学医学院附属第一医院

 

410 Targeting G3BP2 Sensitizes Acute Myeloid Leukemia to Venetoclax Treatment Via ELF1-MCL1 Axis

陈智香，福建医科大学附属协和医院

 

471 Mega-Dose Decitabine Intensified Regimen Is More Effective at Eliminating Pre-HSCT Measurable Residual Disease Compared to the Bu/Cy Regimen: A Multicenter Prospective Phase II Study

Hao Zheng，北京大学人民医院

 

474 The Modified Melphalan-Cladribine-Busulfan-Cyclophosphamide (MCBC) Conditioning Regimen Improved Relapse-Free Survival after Allo-HSCT in Refractory/Relapsed AML

Xiaoyu Zhang，中国医学科学院血液病医院（中国医学科学院血液学研究所）

 

476 Clonal GZMK+CD8+ t Cells Are Identified As a Hallmark of Pathogenesis of Cgvhd-Induced Bronchiolitis Obliterans Syndrome after Allogeneic Hematopoietic Stem Cell Transplantation

肖浩文，浙江大学医学院附属邵逸夫医院

 

480 SLC16A7 Facilitates aGVHD through Regulating Calcium Influx and Lipid Metabolism of CD4+ T Cells

Xiaoxuan Lai，苏州大学附属第一医院

 

524 CD58 Genetic Alterations and Its Contribution to Upregulation of PD-L1 and IDO Via LYN/CD22/SHP1 Axis in DLBCL

Xiyue Xu，天津医科大学肿瘤医院

 

572 KP104, a Bifunctional C5 Antibody/Factor H Fusion Protein, Effectively Controls Both Intravascular and Extravascular Hemolysis: Interim Results from a Phase 2 Study in Complement Inhibitor-Naïve PNH Patients

张凤奎，中国医学科学院血液病医院（中国医学科学院血液学研究所）

 

586 IL1RAP-Specific T Cell Engager (TCE) Antibody Efficiently Depletes Acute Myeloid Leukemia (AML) Leukemic Stem Cells (LSCs)

张仪，浙江大学医学院附属第一医院

 

609 IMM01 Plus Tislelizumab in Prior Anti-PD-1 Failed Classic Hodgkin Lymphoma: An Open Label, Multicenter, Phase 2 Study (IMM01-04) Evaluating Safety As Well As Preliminary Anti-Tumor Activity

周可树，河南省肿瘤医院

 

621 Phase 2 Study to Assess the Safety and Efficacy of Bomedemstat (MK3543) in Combination with Ruxolitinib in Patients with Myelofibrosis

Harinder Gill，香港大学

 

627 HMR Mutations Drive Poor Prognosis in Myelofibrosis Patients with Lower JAK2V617F Allele Burden but Not in Those with Higher Allele Burden: Results of a Multicenter Study

Yu-Hung Wang，国立台湾大学医学院

 

650 Phase I/II Study of Reduced Dosing of Post-Transplantation Cyclophosphamide (PTCy) after HLA-Identical Peripheral Blood Hematopoietic Stem Cell Transplantation

Hang Zhang，四川大学华西医院

 

659 Comparative Study for Haplo, MSD and MUD Allo-Hcts for Core-Binding Factor AML Patients in CR2: A Study from the Global Committee and the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation

叶逸山，浙江大学医学院附属第一医院

 

660 Comparative Study for Haplo, MSD and MUD Allo-Hcts for AML Patients with KMT2A Rearrangement: A Study from the Global Committee and the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation

叶逸山，浙江大学医学院附属第一医院

 

686 Integrin αvβ8-Mediated Activation of TGF-β1 Is Involved in Regulating the Sustained Response after TPO-Ras Withdrawal in ITP Patients

Min Xu，华中科技大学同济医学院附属协和医院

 

687 Efficacy and Safety of Human Umbilical Cord-Derived Mesenchymal Stem Cells in the Treatment of Immune Thrombocytopenia: A Prospective, Single Centre, Single Arm, Phase I Trial

Xu Yanmei，中国医学科学院血液病医院（中国医学科学院血液学研究所）

 

688 The Therapeutic Efficacy of CD19 Chimeric Antigen Receptor T Cells in Immune Thrombocytopenia Model

Yun Wang，山东大学齐鲁医院

 

729 Outcomes of Children and Adolescents with Acute Myeloid Leukemia Given a Low-Versus Standard-Dose Chemotherapy Regimen for Remission Induction (CALSIII-AML18): A Multicenter, Phase 3, Randomized, Noninferiority Trial

Li Gao，苏州大学附属儿童医院

 

736 A Prospective Multicenter Phase II Study of Orelabrutinib-Lenalidomide-Rituximab (OLR) in Patients with Untreated Mantle Cell Lymphoma (MCL) in China (POLARIS Study): Preliminary Analysis on Efficacy, Safety, Mutation Spectrum and Impact of Mutation Profiling on Treatment Responses

张会来，天津医科大学肿瘤医院

 

761 Efficacy Outcomes and Characteristics of Patients with Multiple Myeloma (MM) Who Achieved Sustained Minimal Residual Disease Negativity after Treatment with Equecabtagene Autoleucel (Eque-cel, CT103A) in Fumanba-1

李春蕊，华中科技大学同济医学院附属同济医院

 

778 Safety and Efficacy of Human Amniotic Epithelial Stem Cells Eye Dropin Ocular Chronic Graft-Versus-Host Disease

Xianjing Cheng，陆军军医大学第二附属医院（新桥医院）

 

803 Prednisone Plus Ivig Compared with Prednisone for Immune Thrombocytopenia during Pregnancy

Yuxiu Chen，北京大学人民医院

 

827 Olverembatinib Combined with Venetoclax and Reduced-Intensity Chemotherapy for Patients with Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: Early Results from a Phase II Study

弓晓媛，中国医学科学院血液病医院（中国医学科学院血液学研究所）

 

829 Optimization of Idarubicin and Cytarabine Induction Regimen with Homoharringtonine for Newly Diagnosed AML Based on the Peripheral Blast Clearance Rate: First Result of the Multicenter, Randomized, Phase 3 Trial (RJ-AML 2016)

Yunxiang Zhang，上海交通大学医学院附属瑞金医院

 

834 Venetoclax Plus Azacitidine, Low Dose Cytarabine, Aclarubicin and G-CSF (VA-CAG Regimen) for Newly Diagnosed Young Patients with Acute Myeloid Leukemia: A Prospective, Multicenter, Single-Arm Phase 2 Clinical Trial

Xiaoping Li，中国人民解放军联勤保障部队第九二〇医院

 

846 Clonal Evolution Dissection Reveals High MSI2 Level Promotes Chemo-Resistance in T-Cell Acute Lymphoblastic Leukemia

Jingliao Zhang，中国医学科学院血液病医院（中国医学科学院血液学研究所）

 

857 A Phase II Study of the Efficacy and Safety of the Srmt (Sintilimab, Rituximab, Methotrexate, and Temozolomide) Regimen in Newly Diagnosed Primary Central Nervous System Lymphoma

曾志勇，福建医科大学附属第一医院

 

867 Safety and Efficacy of Tgrx-678, a Potent BCR-ABL Allosteric Inhibitor in Patients with Tyrosine Kinase Inhibitor (TKI) Resistant/Refractory Chronic Myeloid Leukemia (CML): Preliminary Results of Phase I Study

江倩，北京大学人民医院

 

869 Olverembatinib (HQP1351) Demonstrates Efficacy Vs. Best Available Therapy (BAT) in Patients (Pts) with Tyrosine Kinase Inhibitor (TKI)-Resistant Chronic Myeloid Leukemia Chronic-Phase (CML-CP) in a Registrational Randomized Phase 2 Study

江倩，北京大学人民医院

 

879 The Specific Transcriptional Signature and Clonal Selection of MGUS-like Profile Predict an Exceptionally Favorable Prognosis in Patients with Newly-Diagnosed Multiple Myeloma

Wenqiang Yan，中国医学科学院血液病医院（中国医学科学院血液学研究所）

 

889 Efficacy and Safety of Interleukin-6-Knockdown CD19-Targeted CAR T Cells(ssCART-19) for Relapsed/Refractory B-ALL

Lei Yu，上海优卡迪生物医药科技有限公司

 

891 Dasatinib and CAR-T Cell Therapy for Newly Diagnosed Ph-Positive Acute Lymphoblastic Leukemia in Adults

Mingming Zhang，浙江大学医学院附属第一医院

 

969 Venetoclax Combined with Daunorubicin and Cytarabine (2 + 6) in Acute Myeloid Leukemia: Updated Results of a Phase II Trial

索晓慧，邯郸市中心医院

 

970 Comparing the Efficacy and Safety of Venetoclax Combined with Decitabine Versus Conventional Chemotherapy As Induction Therapy for Young Adults with Newly Diagnosed Acute Myeloid Leukemia - Interim Analysis of a Multicenter, Randomized, Phase 2b Trial

卢静，苏州大学附属第一医院

 

1022 Updated Results of a Phase I Open-Label Single-Arm Study of Dual Targeting BCMA and CD19 Fastcar-T Cells (GC012F) As First-Line Therapy for Transplant-Eligible Newly Diagnosed High-Risk Multiple Myeloma

杜鹃，上海长征医院

 

1025 C-CAR039, a Novel Anti-CD20/CD19 Bi-Specific CAR T-Cell Therapy Shows Deep and Durable Clinical Benefits in Patients with Relapsed or Refractory (r/r) B-Cell Non-Hodgkin Lymphoma (B-NHL) in Long Term Follow up

梁爱斌，上海市同济医院（同济大学附属同济医院）

 

1037 Manufacturing of a Subsequent Autologous CAR-T Product after Prior CAR-T Is Safe and Feasible

Yi-Jiun Su，台湾林口长庚医院

 

1039 Neither Conditioning Chemotherapy Nor GvHD-Prophylaxis: CD7 CAR-T Treatment Bridging to Haplo-HSCT

胡永仙，浙江大学医学院附属第一医院

 

1041 Haploidentical Hematopoietic Cell Transplantation Combined with an Unrelated Cord Blood Unit for Adult Acute Myeloid Leukemia Results in Improved Survival Compared to Haploidentical Hematopoietic Cell Transplantation: Results of a Multicenter, Randomized, Phase III Trial

Biqi Zhou，苏州大学附属第一医院

 

Poster Abstracts详细内容请戳：2023 ASH｜中国研究最全汇总，看这一篇就够了！

 

 

排名不分先后，按照摘要号进行排序

如有遗漏或任何问题，请给我们留言~